Moderna Stock News

Moderna, Inc. (NASDAQ:MRNA ) Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ET Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Rose Loughlin - Executive Vice President of Research Conference Call Participants Huidong Wang - Barclays Bank PLC, Research Division Huidong Wang My name is Gena Wang. I'm SMID Cap biotech analyst at the Barclays.

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of high-risk adults aged 18 to 59 years.

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caus...

After soaring to success in the early days of the COVID-19 pandemic, Moderna (MRNA 0.25%) experienced a reversal of fortune. The coronavirus vaccine maker has seen revenue plummet as demand for this flagship product -- Moderna's first to be approved -- has slipped.

Moderna, Inc. (NASDAQ:MRNA ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 8:40 AM ET Company Participants Stéphane Bancel - CEO & Director Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great. Good morning, everyone.

CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event: Barclays Speaking the Science Call Series, on Monday, June 16th at 10:00am ET A live webcast of this presentation will be available under "Events and Presentations" in the Investors section of the Moderna website. investors.modernatx.com.

Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trusted regulatory process and could sow public distrust in vaccinations and federal health agencies.